



MAPS - Updates & Opioid Laws

Kim Gaedeke, Deputy Director Department of Licensing & Regulatory Affairs

Amber Daniels, MAPS Analyst Bureau of Professional Licensing

Conflict of Interest Disclosures; Kim Gaedeke

I do not have any relationships with any entities producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients or any other potential conflicts to disclose.



Conflict of Interest Disclosures; Amber Daniels

I do not have any relationships with any entities producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients or any other potential conflicts to disclose.



Bureau of Professional Licensing

- Established in July 2015
- 10 Occupational Licensing/Regulation Boards
- 27 Health Professional Licensing/Regulation Boards
- Boards are advisory and determine sanctions
- License and regulate over 758,000 individuals
- 3 Divisions: Licensing, Investigations & Inspections, Enforcement
- Enforcement Division: Administers Pharmacy and Drug Monitoring Section and Michigan Automated Prescription System (MAPS) Section; investigates overprescribing, over dispensing, and drug diversion




MAPS Background

- Contains over 120 million records
- Data maintained for 5 years
- Required reporting of CS Schedule 2-5 from:
 - Prescribers who dispense CS Schedule 2-5
 - Pharmacists (dispensers)
 - Veterinarians
- Required as of June 1, 2018 to register and use MAPS:
 - Prescribers




MAPS – NarxCare Integrations






MAPS - NarxCare Report



MAPS – NarxCare Report (continued)





MAPS – NarxCare Report (continued)

02/01/2017	HYDROCODON-ACETAMINOPHN 10	325	60	15	Jo Rya	cvs	0	600.00	40.00	Medicaid	ОН
01/23/2017	OXYCODONE-ACETAMINOPHEN 5-3	25	60	7	Ma Fis	CVS	0	450.00	64.29	Medicaid	ОН
01/12/2017	MORPHINE 2 N S/ML SYRINGE		1	30	No Haw	Wall D	1	6.00	0.20	Private Pay	ОН
01/12/2017	MORPHINE 4 MASML SYRINGE		1	2	No Haw	Wall D	1	12.00	6.00	Private Pay	ОН
01/10/2017	OXYCODONE-ACETAMINOPHEN 5-3	25	120	30	Jo Rya	cvs	0	900.00	30.00	Commercial PBM	ОН
01/07/2017	DEMEROL 25 MG/ML SYRINGE		1	2	Ja Kin	Wall D	1	7.50	3.75	Private Pay	ОН
01/03/2017	HYDROCODON-ACETAMINOPHEN 5	-325	60	8	Ja Nic	CVS	0	300.00	37.50	Medicaid	ОН
12/26/2016	HYDROCODON-ACETAMINOPHEN 5	-325	60	8	Ja Nic	Wall D	0	300.00	37.50	Commercial PBM	ОН
12/11/2016	HYDROCODON-ACETAMINOPHEN 5	-325	28	5	He Hol	CVS	0	140.00	28.00	Private Pay	ОН
12/07/2016	HYDROCODON-ACETAMINOPHEN 5	-325	14	7	Pa Mar	CVS	0	70.00	10.00	Commercial PBM	ОН
12/07/2016	HYDROCODON-ACETAMINOPHEN 5	-325	2	2	Pa Mar	Wall D	1	10.00	5.00	Private Pay	ОН
11/07/2016	HYDROCODON-ACETAMINOPHEN 5	-325	10	5	Pa Mar	CVS	0	50.00	10.00	Private Pay	ОН
11/06/2016	HYDROCODON-ACETAMINOPHEN 5	-325	1	2	Ru Har	Wall D	1	5.00	2.50	Private Pay	ОН
08/01/2016	OXYCODONE-ACETAMINOPHEN 5-3	25	20	3	Br Fer	Wall D	0	150.00	50.00	Commercial PBM	ОН
11/12/2015	MORPHINE 2 MG/ML SYRINGE		1	30	Pa Mar	Wall D	1	6.00	0.20	Private Pay	ОН
Providers	Total Providers: 15										
Name	•	Address				•	State	\$	Zipcode	♦ DEA	\$
Fernandez, E		4367 Pleasant Cre	neeina		Five Poi	•	ОН	•	44262-681		•
Fisher, Marie		7175 Cozy Rabbit	_		Anderso		ОН		43622-129		
Harris, Ruth		2003 Stony Necta				s Corners	ОН		45983-367		
Hawkins, No	rma	6763 Emerald Rol		av	Apple G		ОН		45273-058		
Holmes, Hele		8869 Burning Fox		-,		ailer Court	ОН		45202-979		
Jenkins, Ger		9393 Lost Field			Maple		ОН		43654-827		
Kennedy, Be		3099 Umber Path	wav		Damasc	us	ОН		44609-590		
King, James		3355 Rustic Cloud	d Wvnd		Yankee	Crossing	ОН		45430-618	8 234845	
Lane, Arthur		2331 Cozy Port	•		Holiday	_	ОН		45620-598	7 234844	
Martin, Patrio		7600 Shady Hicko	rv Stead		Fort Jen	-	ОН		44170-284	7 234850	
Nichols, Jaso		9093 Hidden Pion	-	out	East Ga	_	ОН		43321-433	1 234848	
Ramos, Jess		9166 Bright Pond			Belmore		ОН		45970-989	9 234840	
Ray, Ralph		1467 Little View T			West Ak	ron	ОН		43739-735	1 234849	
Ryan, Jerry		163 Sleepy Edge			Oakthor	oe .	ОН		44740-512	234846	
Ryan, Jonath	nan	9892 Silent Elk Ra	amp			ke Cottage Area	ОН		44502-580		
2											



MAPS – NarxCare Report (continued)

Pharmacies	Total Pharmacies: 6										
Name	\$	Address	\$	City	\$	State	\$	Zipcode	\$	DEA	\$
cvs		5483 Gentle Impasse		Home Park		ОН		43242-6009		345796	
CVS		7139 High Pond Walk		Randolph Landing		ОН		45487-2143		345840	
Wall Drug		3799 Foggy Dale		Herner Corners		ОН		45658-6817		345841	
Wall Drug		4543 Iron Carrefour		Powers		ОН		43803-2784		345839	
Wall Drug		5639 Cotton Dale Close		Cedar Springs		ОН		43423-4846		345842	
Wall Drug		8129 Easy Dell		Antiquity		ОН		45300-0810		345843	
								6	Appriss	2017. All rights	reserved.



MAPS – NarxCare

- Narx Scores and Predictive Risk Scores (overdose)
 - Scores: based on algorithms, including MMEs, number of prescribers and pharmacies
 - > Scores: Ranges from 000-999; higher scores equate to higher risk and misuse
- Red Flags
- Rx Graphs
- PDMP Data
- Used as a tool to help make informed decisions, but should not be the sole basis on how a clinician treats his/her patients.




Integrations & Registrations as of October 2018

MAPS Integrations							
	In-Production	Pending Production (In- discussion, received request, or in-testing)					
Health System	16	8					
Hospital	62	35					
Number of Prescribers	28,641	18,104					
Number of Pharmacies	413	13					
Total Number of Healthcare Professionals	30,887	18,894					
TOTAL	30,954	37,054					

MAPS Online Registered Users							
	As of 04/04/2017 ("Go-Live")	As of 10/31/2018					
Prescribers	9,156	41,984					
Pharmacists	3,994	7,996					
Delegates	1,096	17,189					
TOTAL	14,246	67,169					



MAPS – Patient Requests



Bureau of Professional Licensing

Complaint & Enforcement Process



Filing A PHC Complaint with BPL

- Nursing profession complaints submitted online
- All other health professions submitted using BPL's Complaint Form
- Complaints are submitted to BPL's Investigations and Inspections Division

May we release yo	our name and this
information to the	practitioner?
□Yes	□No



BPL/IID-200 (01/17)

Michigan Department of Licensing and Regulatory Affairs

Bureau of Professional Licensing Investigations & Inspections Division P.O. Box 30670 Office Use Only File #:

Lansing, MI 48909-8170 (517) 373-9196 COMPLAINT FORM

Authority: Public Act 368 of 1978, as amended

Completion: Voluntary Penalty: None

Please be advised this agency DOES NOT assist citizens seeking reimbursement or resolution of billing or fee disputes or investigate anonymous complaints. In addition, this agency DOES NOT handle complaints against health care facilities.

INSTRUCTIONS: Print legibly or type information. Complete all sections of this form. Sign at the bottom. Return the form to the address above. Please complete a separate form for each practitioner you are filling a complaint against.

Your Name	ion About You		Practitioner's First and Last	: Being Filed Against Name			
Street Address			Street Address				
City			City				
State Zip	Code Countr	ry	State Zip Code				
Patient's Name			Practitioner's Telephone Nur	mber			
Patient's Date of Birth (MM/DE	D/YYYY)		Treatment/Incident Date				
Patient's Last 4 Digits of Their	Social Security Number		communicate with the Depa	a person other than yourself to rtment regarding your complaint?			
Your Telephone Numbers With	Area Code		□Yes □No				
Cell:			Name:				
Home:	Work:		Address: Telephone Number: Relationship to You:				
Check the profession for w Acupuncture Allopathic Physician (MD) Athletic Trainer Audiologist Chiropractor Counselor Dentistry	hich you are lodging a Marriage & Fami Massage Therap Nurse (RN or LP Nursing Home A Physician's Assis	ily Therapist bist (N) dministrator stant	Dabout: Osteopathic Physician (DD) Pharmacist Pharmacist Physician (Physical Therapist Veterinarian Physical Therapist Psychologist Psychologist	Respiratory Therapist Sanitarian Social Worker Speech/Language Pathologis			
inform		informa	release your name and this tion to the practitioner?	Will you testify at an Administrative Hearing if necessary?			
□Yes □No	Yes No	- 10-]Yes □No	□Yes □No			
Please provide details of yo	our specific concerns r	elated to the	e treat int rendered. Attac	ch additional sheets if necessary.			

The Department of Licensing and Regulatory Affairs will not discriminate against any individual or group because of race, sex, religion, age, national origin, color, marital status, disability or political beliefs. If you need assistance with reading, writing, hearing, etc., under the Americans with Disabilities Act, you may make your needs known to this agency.

Filing A PHC Complaint with BPL- FAQs

Q: Do I have to report a colleague who may have violated the Public Health Code?

- MCL 333.16222(1)
- A licensee or registrant who has knowledge that another licensee or registrant has committed a violation under section 16221, article 7, or article 8 or a rule promulgated under article 7 or article 8 shall report the conduct and the name of the subject of the report to the department.
- Failure of a licensee or registrant to make a report under this subsection does not give rise to a civil cause of action for damages against the licensee or registrant, but the licensee or registrant is subject to administrative action under sections 16221 and 16226.

Q: Will my identity remain confidential?

- MCL 333.16222(2)
- Unless the licensee or registrant making a report under subsection (1) otherwise agrees in writing, the identity of the licensee or registrant making a report under subsection (1) shall remain confidential unless disciplinary proceedings under this part are initiated against the subject of the report and the licensee or registrant making the report is required to testify in the proceedings.


Q: Do I have to report a colleague who may be impaired?

- MCL 333.16223
- reasonable cause to believe that a licensee, registrant, or applicant is impaired **shall** report that fact to the department.
- A licensee or registrant who fails to report under this subsection is not liable in a civil action for damages resulting from the failure to report, but the licensee or registrant is subject to administrative action under sections 16221 and 16226.
- A licensee or registrant who in good faith complies with this section is not liable for damages in a civil action or subject to prosecution in a criminal proceeding as a result of the compliance.



The PHC Complaint/Enforcement Process

- Complaint is submitted to and reviewed by the Inspections and Investigations Division
 - closed or authorized for investigation
- Complaint is investigated
 - Closed, referred to expert, or transferred to Enforcement Division for drafting of Administrative Complaint and possible Order of Summary Suspension



OSS can be mandatory or discretionary

- Licensee receiving
 Administrative Complaint elects
 either
 - A compliance conference, settlement, or formal administrative hearing
 - Failure to respond results in automatic sanctions imposed by a Board's Disciplinary Subcommittee (DSC) via a Final Order
- Licensee receiving Order of Summary Suspension and Administrative Complaint
 - Cannot practice until matter is resolved through the administrative hearing process



The PHC Complaint/Enforcement Process- Continued

- If the Department proposes settlement terms
 - If Licensee agrees to terms, a Consent Order and Stipulation is drafted. After Licensee and the Department sign the document, it is forwarded to the Board's DSC for review
 - The DSC either approves the Consent Order and Stipulation, making it legal and binding, or rejects it and proposes a counter offer
 - If a settlement cannot be reached, the matter is forwarded for a formal administrative hearing
- If the matter goes through the formal administrative hearing process
 - Based on the issuance of an Administrative Complaint and OSS, Licensee's election, or a failure to reach a settlement
 - The DSC either approves the Proposal for Decision making it legal and binding, dismisses the Administrative Complaint based on the Administrative Law Judge's (ALJ) findings, or reverses the ALJ and makes its own findings of fact and conclusions of law
- Licensee may appeal the DSC's decision to the Michigan Court of Appeals
- If no appeal, the Department monitors Licensee's compliance with further sanctions for noncompliance



Legislative Action

New Opioid Laws





Requires disclosure of opioid information to minors and patients.

- Beginning <u>June 1, 2018</u>, a prescriber shall comply with the following before issuing a new prescription for a controlled substance containing an opioid to a minor:
 - ➤ Discuss with the minor and the minor's parent or guardian the potential risks of addiction and overdose associated with the controlled substance.
 - ➤ Discuss the increased risk of addiction to a controlled substance to an individual suffering from both mental and substance abuse disorders.
 - ➤ Discuss the danger of taking a controlled substance containing an opioid with benzodiazepine, alcohol, or another central nervous system depressant.
 - > Discuss any other information in the patient counseling information section of the label for the prescription.





- Requires the signature of the minor's parent or guardian to consent to the minor's treatment on a
 "start talking consent form", which is to be filed in the minor's medical record.
- The form is to contain:
 - Signatures of the parties involved.
 - > Information on the name and quantity of the controlled substance.
 - Acknowledgement that the drug has potential for abuse.
 - A statement certifying that the prescriber discussed with the minor and the minor's guardian the potential risks of the drug.
- If an adult signing a consent form is not the parent or guardian, the prescriber shall not prescribe more than a single 72-hour supply of the controlled substance to the minor.





- Exceptions to the law in case of emergency:
 - > If it is detrimental to the minor's health.
 - Certain surgical circumstances.
 - Specific hospice related instances.
 - > If the minor's parent or guardian is not legally required to consent.
- Beginning <u>June 1, 2018</u>, before an opioid is prescribed to a patient, a prescriber shall provide the following information:
 - > The dangers of opioid addiction.
 - How to properly dispose of an expired, unused, or unwanted controlled substance.
 - > That the delivery of a controlled substance is a felony under Michigan Law.
 - ➤ If the patient is pregnant or is a female of reproductive age, the short and long term effects of exposing a fetus to an opioid, including but not limited to neonatal abstinence syndrome.





- The prescriber shall obtain the signature of the patient or the patient's representative on a form provided by the Department of Health and Human Services, that they were informed of the above requirements. The form can be found at michigan.gov/stopoverdoses under the prescriber tab.
- The signed form shall be kept in the patient's medical record.
 - > The requirement does not apply if the controlled substance is prescribed for inpatient use
- Provides sanctions for prescribers for failing to inform minors and their guardians of the risks of opioid abuse.



Public Act 247 of 2017 (PA 101 of 2018)



Please note this law was amended with PA 101 of 2018, which extends the effective date to March 31, 2019 unless LARA promulgates rules to provide exceptions to the bona-fide prescriber-patient relationship for prescribing.

Requires prescribers to be in bona-fide prescriber-patient relationships prior to prescribing.

- Beginning March 31, 2019, a licensed prescriber shall not prescribe a controlled substance listed in Schedules 2-5 unless the prescriber is in a bona fide prescriber-patient relationship with the patient.
- If the prescriber provides a controlled substance, the prescriber shall provide follow-up care to the patient to monitor the efficacy of the use of the controlled substance as a treatment of the patient's medical condition.



Public Act 247 of 2017 (PA 101 of 2018)



- If the prescriber is unable to provide follow-up care, they shall refer the patient to the patient's primary care provider for follow-up care, or if a primary care provider does not exist, another licensed prescriber who is geographically accessible to the patient.
- Defines a bona fide prescriber-patient relationship as treatment or a counseling relationship between a prescriber and a patient in which both of the following are present:
 - The prescriber has reviewed the patient's relevant medical or clinical records and completed a full assessment of the patient's medical history and current medical condition, including a relevant medical evaluation of the patient conducted in person or via telehealth.
 - > The prescriber has created and maintained records of the patient's condition in accordance with medically accepted standards.



Public Act 247 of 2017 (PA 101 of 2018)



- LARA, in consultation with its board(s), may promulgate rules:
 - ➤ Describing circumstances under which a bona fide prescriber-patient relationship is not required for purposes of prescribing a Schedule 2 to 5 controlled substance.
 - ➤ The rules may also include an alternative requirement for prescribing a Schedule 2 to 5 controlled substance when a bona fide prescriber-patient relationship is not required by the rules.
- Provides terms for sanction for violating the bona fide relationship requirements.
- Please note with PA 101 of 2018, the December 27, 2018 deadline for rule promulgation does not apply.





Requires prescribers to be registered to MAPS prior to prescribing or dispensing a controlled substance, and also requires a review of MAPS when prescribing or dispensing in a quantity that exceeds a 3-day supply.

- Beginning <u>June 1, 2018</u>, before prescribing or dispensing to a patient a controlled substance in a quantity that exceeds a 3-day supply, a licensed prescriber shall obtain and review a MAPS report concerning that patient. The requirement does not apply in any of the following circumstances:
 - ➤ If the dispensing occurs in a hospital or a freestanding surgical outpatient facility and the controlled substance is administered to the patient in the hospital or facility.
 - ➤ If the patient is an animal, the dispensing occurs in a veterinary hospital or clinic, and the controlled substance is administered to the animal in that hospital or clinic.
 - ➤ If the controlled substance is prescribed by a licensed prescriber who is a veterinarian and the controlled substance will be dispensed by a pharmacist.
- Beginning <u>June 1, 2018</u>, before prescribing or dispensing a controlled substance to a patient, a licensed prescriber shall register with MAPS.





Contains provisions for sanction for various violations of the opioid bills package.

- Contains many of the provisions of the other bills, as it is being used as a vehicle to correct conflicts
 in statute created by the package of bills being passed.
 - > Includes the bona fide prescriber-patient relationship language of PA 247 of 2017.
 - ➤ Contains the mandatory MAPS report review language for prescribers contained in PA 248 of 2017, as well as language regarding mandatory registration with MAPS for prescribers.





- Provides penalties for violation of the following:
 - ➤ Beginning March 31, 2019, prescribers failing to adhere to the bona fide prescriber-patient relationship requirements.
 - ➤ Beginning <u>June 1, 2018</u>, prescribers failing to obtain and review a MAPS report, when required, prior to prescribing or dispensing to a patient a controlled substance in a quantity that exceeds a 3-day supply.
 - ➤ Beginning <u>June 1, 2018</u>, prescribers failing to register with MAPS prior to prescribing or dispensing a controlled substance to a patient.
 - ➤ Beginning <u>June 1, 2018</u>, prescribers failing to provide minors, and their parents or guardians, with proper education regarding the risks of opioid abuse.





- Beginning June 1, 2018, if the department has reasonable basis that a licensee failed to obtain and review a MAPS report or failed to register to MAPS, LARA:
 - > Is not required to conduct an investigation.
 - May issue a letter to the licensee notifying Issue Includes the bona fide prescriber-patient relationship language of PA 247 of 2017.
 - > A letter issued under this section of the law is not considered a disciplinary action.
- Not registering and checking MAPS may result in sanctions as determined by the board.



Public Act 250 of 2017



Requires the providing of information regarding Substance Use Disorder Services.

- Effective **March 27, 2018**:
 - A health professional licensee or registrant that treats a patient for an opioid-related overdose is required to provide that patient with information regarding Substance Use Disorder Services.



Public Act 251 of 2017



Requires prescribers treating for acute pain, to not prescribe a patient more than a 7-day supply of an opioid within a 7-day period.

- Beginning July 1, 2018, if a prescriber is treating a patient for acute pain, that the prescriber shall not prescribe the patient more than a 7-day supply of an opioid within a 7-day period.
- Further, beginning March 27, 2018, the legislation provides that a pharmacist, consistent with federal law and regulations on the partial filling of a controlled substance included in Schedule 2, may partially fill in increments, a prescription for a controlled substance included in Schedule 2.



Public Act 252 of 2017



MAPS review requirements before dispensing or prescribing buprenorphine or methadone.

- Effective March 27, 2018.
- Adds the dispensing of a controlled substance at a veterinary hospital or clinic that administers the controlled substance to an animal that is an inpatient, to the following list of exemptions for MAPS reporting requirements:
 - A hospital.
 - ➤ A health facility or agency if the controlled substance is dispensed by a dispensing prescriber in a quantity adequate to treat the patient for not more than 48 hours.



Public Act 252 of 2017



- Provides that before dispensing or prescribing buprenorphine or a drug containing buprenorphine or methadone to a patient in a substance disorder program, that a prescriber shall obtain and review a MAPS report on the patient.
- Additionally, the legislation provides that a prescriber shall report data to MAPS if federal law does
 not prohibit the reporting of data concerning the patient, to LARA.
- The legislation rescinds R 338.3162E from the pharmacy rules, which deals with exemptions to MAPS reporting requirements.



Public Act 253 of 2017



Medicaid eligibility for Substance Use Disorder Services.

- Effective March 27, 2018.
- Amends the Social Welfare Act to provide that an eligible individual can receive medically necessary treatment for opioid abuse. The bill codifies coverage by Michigan's Medicaid program for detox programs.





PDOAC recommendations for the instruction of pupils on the dangers of opioid abuse.

Requires PDOAC, by <u>July 1, 2018</u>, to develop or adopt for Michigan's Department of Education,
 recommendations for the instruction of pupils on the dangers of prescription opioid drug abuse.



Public Act 255 of 2017



MDE model programs of instruction on the dangers of prescription opioid drug abuse.

- No later than <u>July 1, 2019</u>, the Department of Education shall make available to school districts the model program of instruction on the dangers of prescription opioid drug abuse, developed or adopted by PDOAC.
- Beginning in the <u>2019-2020 School Year</u>, the Department of Education shall ensure that the state model of academic standards for health education includes instruction on prescription opioid drug abuse, including at least the PDOAC recommendations.



Public Act 101 of 2018



- Pushes back the effective date for the bona fide prescriber-patient relationship requirement to 3/31/19; OR
- If rules are promulgated to provide alternatives to the prescriber-patient requirement before 3/31/19, on the date on which rules are promulgated is when the change becomes effective.



Additional Legislative Information



- Individuals seeking additional information regarding the new opioid laws can visit http://www.legislature.mi.gov and do the following:
 - Select "Public Act (Signed Bills)" among the options under the "Legislature" category on the left of the page.
 - On the "Public Acts" webpage, enter the Public Act Number, and select a "Public Act Year" below. For example, to find more information regarding Public Act 247 of 2017, Enter "247" in the search box, and select the "Public Act Year" from the dropdown box as "2017". Select "Search" when ready.
- A direct link to the above referenced "Public Act (Signed Bills)" search page is as follows:
 - http://www.legislature.mi.gov/(S(gfsic4rztsd0vhcpbmxfjwvy))/mileg.aspx?page=PublicActs.



Additional Resources & Information



LARA and DHHS have produced FAQs regarding the new Opioid Laws, which are posted online at:

- www.Michigan.gov/bpl
 - > Michigan Automated Prescription System (MAPS)
 - > Laws/Regulations
 - > Michigan Opioid Laws Frequently Asked Questions
- https://www.michigan.gov/documents/lara/LARA DHHS Opioid Laws FAQ 05-02-2018 622175 7.pdf

For information about integrating MAPS with your EMR, visit:

www.Michigan.gov/mimapsinfo

For additional information about the opioid issue for both the public and providers, please visit the State website at:

www.Michigan.gov/opioids



Questions?

Special <u>THANK YOU</u> goes to all our Appropriators and Legislators for partnering with Governor Snyder, and Lt. Governor Calley in supporting our efforts to fully replace MAPS as we continue to make it a more robust preventative tool for providers to use in the fight against the Opioid Epidemic.

Also huge thanks BJA, SAMHSA, CDC, and the Michigan Department of Health and Human Services for the grant funds and partnership. We also appreciate our BPL team, Boards, Law Enforcement, and Health Care Associations for being engaged and involved Stakeholders.

Thank you to the DEA for coordinating this training and for their collaboration with LARA.

